Merck KGaA Overcomes Ukraine Disruption To Keep MS Frontrunner On Track

FDA Has Approved Trial Adaptations

 
• By Andrew McConaghie
Merck KGaA Darmstadt
Evobrutinib is one of two Phase III assets which Merck KGaA believes can achieve $1bn plus annual revenues • Source: Shutterstock

More from Business

More from Scrip